Jeffrey Kordower to Gene Transfer Techniques
This is a "connection" page, showing publications Jeffrey Kordower has written about Gene Transfer Techniques.
Connection Strength
1.452
-
Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med. 2011 Jan-Feb; 78(1):126-58.
Score: 0.362
-
Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
Score: 0.263
-
Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Ther. 2022 06; 29(6):390-397.
Score: 0.184
-
Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
Score: 0.160
-
Trophic factor gene therapy for Parkinson's disease. Mov Disord. 2013 Jan; 28(1):96-109.
Score: 0.104
-
Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis. 2009 Nov; 36(2):303-11.
Score: 0.082
-
Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2009 Apr; 34(1):40-50.
Score: 0.079
-
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
Score: 0.069
-
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
Score: 0.068
-
Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
Score: 0.044
-
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009 Apr; 64(4):602-12; discussion 612-3.
Score: 0.020
-
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S469-77.
Score: 0.017